GW-7647

{{Drugbox | Verifiedfields = changed | verifiedrevid = 477241234 | IUPAC_name = 2-[[4-[2-(1H-tetrazol-5-yl)ethyl]phenyl]sulfanyl]-2-methylpropanoic acid | image = GW7647_structure.png | width = 200 | CAS_number = 265129-71-3 | PubChem = 9821415 | ChemSpiderID = 7996484 | UNII = 0F8V5QZK3Q | KEGG = D09345 | ChEMBL = 2103870 | C=14 | H=16 | N=4 | O=2 | S=1 | molecular_weight = 304.37 }}

GW-7647 is a potent and selective agonist of the peroxisome proliferator-activated receptor alpha (PPARα), a type of nuclear receptor that plays a crucial role in the regulation of lipid metabolism and energy homeostasis. This compound has been extensively studied for its potential therapeutic applications in metabolic disorders, including dyslipidemia, atherosclerosis, and type 2 diabetes mellitus.

Mechanism of Action

GW-7647 functions by binding to the ligand-binding domain of PPARα, which is predominantly expressed in tissues with high rates of fatty acid oxidation, such as the liver, heart, and skeletal muscle. Upon activation by GW-7647, PPARα forms a heterodimer with the retinoid X receptor (RXR) and binds to specific response elements in the DNA, leading to the transcriptional regulation of genes involved in fatty acid transport, β-oxidation, and lipoprotein metabolism.

Pharmacological Effects

The activation of PPARα by GW-7647 results in several beneficial effects on lipid metabolism:

• Increased Fatty Acid Oxidation: GW-7647 enhances the expression of genes involved in mitochondrial and peroxisomal β-oxidation pathways, leading to increased breakdown of fatty acids.
• Improved Lipid Profile: It reduces plasma triglyceride levels and increases high-density lipoprotein (HDL) cholesterol levels, contributing to a more favorable lipid profile.
• Anti-inflammatory Effects: GW-7647 has been shown to exert anti-inflammatory effects by downregulating the expression of pro-inflammatory cytokines and adhesion molecules.

Research and Development

GW-7647 has been primarily used as a research tool to study the role of PPARα in metabolic processes. Its high selectivity and potency make it an ideal candidate for investigating the physiological and pathological roles of PPARα activation. However, its development as a therapeutic agent has been limited due to potential side effects and the availability of other PPARα agonists with established clinical efficacy, such as fibrates.

Potential Clinical Applications

While GW-7647 itself is not used clinically, the insights gained from its study have contributed to the understanding of PPARα as a therapeutic target. This has implications for the treatment of conditions such as:

• Hyperlipidemia: By improving lipid profiles, PPARα agonists can help manage elevated cholesterol and triglyceride levels.
• Cardiovascular Disease: The anti-inflammatory and lipid-modulating effects of PPARα activation may reduce the risk of atherosclerosis and related cardiovascular events.

Safety and Side Effects

As with other PPARα agonists, potential side effects of GW-7647 include liver toxicity, muscle pain, and gastrointestinal disturbances. These effects underscore the importance of careful dose management and patient monitoring in the development of PPARα-targeted therapies.

Also see

• Peroxisome proliferator-activated receptor
• Fibrate
• Lipid metabolism
• Nuclear receptor